Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics Inc (NQ: CYTH )

0.8700 +0.0500 (+6.10%)
Streaming Delayed Price Updated: 12:09 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,739
Open 0.8686
Bid (Size) 0.8364 (1)
Ask (Size) 0.8740 (13)
Prev. Close 0.8200
Today's Range 0.8230 - 0.8750
52wk Range 0.8190 - 3.350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
 
Via Benzinga
Cyclo Therapeutics's Return On Capital Employed Insights
 
Via Benzinga

Performance

YTD
-38.73%
-38.73%
1 Month
-41.22%
-41.22%
3 Month
-39.58%
-39.58%
6 Month
-55.61%
-55.61%
1 Year
-70.21%
-70.21%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results
From Cyclo Therapeutics
Via Business Wire
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements
From Cyclo Therapeutics
Via Business Wire
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
From Cyclo Therapeutics, Inc.
Via Business Wire
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Via Benzinga
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics, TRACON Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.